Amphastar Pharmaceuticals (AMPH) Wells Fargo 20th Annual Healthcare Conference 2025 summary

Company Overview and Strategic Direction

• Operates a vertically integrated model from R&D to distribution, with 1,500 employees and over a decade as a public entity, ensuring quality and compliance throughout the product lifecycle.

• Strategic focus on expanding the proprietary pipeline to 50% and biosimilars to 35% by 2026, with ongoing business development and acquisitions as growth levers.

• Recent licensing and in-licensing of preclinical oncology and ophthalmology assets signal diversification and long-term growth ambitions.

• Emphasis on leveraging peptide manufacturing expertise and advanced technologies for new therapeutic areas and future launches.

• Revenue reached $732 million in 2024, with adjusted net income margin increasing to 27.4%.

Pipeline Evolution, R&D Investment, and Product Launches

• Substantial R&D investment of $351 million over five years supports a diverse and scalable product portfolio, with six generic pipeline candidates in advanced stages.

• Proprietary and biosimilar products projected to comprise 85% of the 2026 pipeline.

• Iron sucrose launched in August, targeting 20–25% market share with a six-month exclusivity window.

• Teriparatide (AMP-015) expected to receive approval in Q4 2025, with optimism based on review progress and market stability.

• AMP-007 inhalation ANDA on track for 1H 2026, with potential first-to-market generic advantage and minimal risk of patent litigation.

Key Products and Commercial Performance

• Baqsimi scripts have grown at double-digit rates year-to-date, with high single-digit unit growth guidance for 2024, and projected peak sales of $250–$275 million.

• Primatene Mist achieved 10% year-over-year growth in H1 2025, surpassed $100 million in 2024 sales, and is forecasted for continued growth.

• Market penetration for glucagon among insulin users increased from 10% to 12%, with a focus on compliance and sales force effectiveness.

• Existing products provide a strong revenue base, with new launches supporting diversification.

• Sales and adjusted EPS have grown at 20% and 57% CAGR, respectively, from 2020 to 2024.